Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mXELOXIRI is a combination chemotherapy regimen used primarily in the treatment of advanced or metastatic colorectal cancer. The name "mXELOXIRI" stands for "modified XELOX + irinotecan," indicating it is a modified version of the XELOX (capecitabine plus oxaliplatin) regimen with the addition of irinotecan. This protocol typically includes capecitabine (an oral prodrug of 5-fluorouracil), oxaliplatin (a platinum-based chemotherapeutic), and irinotecan (a topoisomerase I inhibitor). The modification ("m") usually refers to dose adjustments or scheduling changes to improve tolerability or efficacy compared to standard regimens. These agents work synergistically by interfering with DNA synthesis and repair, leading to cancer cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mXELOXIRI.